#AACR20: Ear­ly da­ta sug­gest No­var­tis' In­cyte-dis­cov­ered MET in­hibitor helps lung can­cer pa­tients with brain le­sions

Months af­ter cap­ma­tinib — the MET in­hibitor de­signed to cross the blood-brain bar­ri­er dis­cov­ered by In­cyte and li­censed by No­var­tis — se­cured the FDA’s pri­or­i­ty re­view in pa­tients with a form of lung can­cer, the Swiss drug­mak­er has re­port­ed en­cour­ag­ing, al­beit ear­ly, da­ta in pa­tients whose can­cer had spread to the brain.

Da­ta from 13 pa­tients with metasta­t­ic MET ex­on 14 skip­ping non-small cell lung can­cer with brain metas­tases, were un­veiled at the vir­tu­al­ly-held Amer­i­can As­so­ci­a­tion for Can­cer Re­search con­fer­ence on Mon­day.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.